Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994030 | 1.00 | HTR2C (0.45) | HTR2CCHRM2CHRM4CHRNB2CHRNB4 | |
| SCHEMBL23994065 | 1.00 | HTR2C (0.45) | HTR2CCHRM2CHRM4CHRNB2CHRNB4 | |
| SCHEMBL23994772 | 1.00 | HTR2C (0.45) | HTR2CCHRM2CHRM4CHRNB2CHRNB4 | |
| SCHEMBL25005770 | 0.89 | HTR2C (0.43) | HTR2CCHRM2CHRM4CHRNB2CHRNB4 | |
| SCHEMBL16393865 | 0.86 | SLC6A2 (0.37) | HTR2CSLC6A3KDM1AMAOA | |
| SCHEMBL18853849 | 0.86 | SLC6A2 (0.37) | HTR2CSLC6A3KDM1AMAOA | |
| SCHEMBL16393864 | 0.86 | SLC6A2 (0.37) | HTR2CSLC6A3KDM1AMAOA | |
| SCHEMBL30181776 | 0.83 | HTR2C (0.50) | HTR2CCHRM2KDM1ARCOR1 | |
| SCHEMBL3752918 | 0.83 | KDM1A (0.43) | HTR2CSLC6A3KDM1ARCOR1 | |
| SCHEMBL31381542 | 0.83 | KDM1A (0.43) | HTR2CSLC6A3KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | HTR2C 1699/4885CHRM2 2619/4885CHRM4 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.